Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital
About this trial
This is a prospective, multicenter observational study for recipients of hematopoietic stem cell transplantation. Patients who underwent hematopoietic stem cell transplantation at the participating centers will be entrolled in the study. The clinical characteristics, laboratory profiles, management measures, and clinical outcomes such as post-transplant cardiovascular events will be prospectively collected.
Eligibility criteria
Qualifiers
Patients who undergo hematopoietic cell transplantation at any of the participating medical centers.
Disqualifiers
Any other conditions that, in the opinion of the investigator, can interfere with the interpretation of data.
Patient request to withdraw from the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
10,000 Participants
are grouped into 1 trial groupSponsors and collaborators
Peking University People's Hospital
Lead sponsor
Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
Collaborator
First Affiliated Hospital of Zhejiang University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Tongji Hospital
Collaborator
Xinqiao hospital of the third military medical university
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Sun Yat-Sen University Cancer Center
Collaborator
Sichuan Provincial People's Hospital
Collaborator
First Affiliated Hospital of Harbin Medical University
Collaborator
First Affiliated Hospital Xi'an Jiaotong University
Collaborator
First Affiliated Hospital of Xinjiang Medical University
Collaborator
Chinese PLA General Hospital
Collaborator
Peking University Shenzhen Hospital
Collaborator
Peking University Third Hospital
Collaborator
Peking University First Hospital
Collaborator
Source ClinicalTrials.gov